Rituxan Approved to Treat Severe Pemphigus Vulgaris
The U.S. Food and Drug Administration has approved Genentech’s Rituxan (rituximab) to treat moderate-tosevere phemphigus vulgaris.
FDA Approves Fast-Acting, Single-Dose Flu Medication
The U.S. Food and Drug Administration (FDA) has approved a new, single-dose medication to treat people 12 years and older who have had the flu for no more than 48 hours.
FDA Approves First Treatment for High-Risk Prostate Cancer
The U.S. Food and Drug Administration has approved Erleada (apalutamide) to treat men with prostate cancer that has not yet spread but has a quickly rising PSA level while on treatment with hormone therapy, which causes concern for cancer growth and spread.
Updated C. Diff Guidelines Reflect New Treatment Options and Recommendations
The Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) have updated guidelines for diagnosis and management of Clostridium difficile (C. diff).
Frequency-Escalated Prophylaxis for Severe Hemophilia A Reduces Clotting Factor Usage with Minimal Long-Term Arthropathy
A longitudinal study of Canadian boys with severe hemophilia showed that tailored frequency-escalated prophylaxis results in minimal long-term arthropathy and very good health outcomes, while reducing the quantity of costly clotting factor as compared with standard prophylaxis protocols.
Medical Marijuana and the Opioid Crisis
Can marijuana be used as an adjunct to or substitute for opioids in the treatment of chronic pain
to potentially alleviate the opioid crisis?
The Future of Cord Blood
Once thought to be a useless byproduct, umbilical cord blood now treats more than 80 diseases, and it may soon be used to treat more.
Chronic Human Albumin Therapy Prolongs Survival in Patients with Decompensated Cirrhosis
Results from a clinical trial have led investigators to conclude adding longterm administration of human albumin to conventional treatment inpatients with decompensated cirrhosis appears to prolong survival.
Grifols’ Higher-Potency Rabies Immune Globulin Is Now Available
Grifols’ higher-potency rabies immune globulin (RIG), HyperRAB S/D, was made available to healthcare providers
Updated C. Diff Guidelines Reflect New Treatment Options and Recommendations
The Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) have updated guidelines for diagnosis and management of Clostridium difficile (C. diff).
